DSIP 10 mg

DSIP 10 mg is a research peptide studied for its effects on sleep architecture and neuroendocrine signaling. It is a naturally occurring nonapeptide originally isolated from rabbit cerebral venous blood. It has never been approved for human use and is sold strictly for laboratory research purposes.

No established human dosing protocol exists. In non-medical community contexts, the convention commonly quoted is 100 to 300 mcg subcutaneously, 30 to 60 minutes before bed, often cycled a few weeks on and a few weeks off. Some protocols reference 100-800 mcg 1-2 nights per week to prevent tachyphylaxis.

DSIP has no relationship to the hypothalamic-pituitary-gonadal axis and is not part of any post-cycle therapy protocol. Its research focus has been on sleep architecture and neuroendocrine signaling, not hormonal recovery. PCT compounds such as Clomid and Nolvadex address entirely different biological systems.

DSIP is a neuropeptide found in neurons, peripheral organs, and plasma. It is described as inducing mainly delta sleep in mammals and has been observed to affect electrophysiological activity, neurotransmitter levels, circadian and locomotor patterns, hormonal levels, and the activity of neuropharmacological drugs. Its mechanism of action remains to be established.

DSIP has a commonly cited half-life of around 15 minutes, with a peak within a few minutes. In non-medical community protocols, users typically report mild subjective effects in the first 1-3 nights, with measured deep-sleep minutes climbing around nights 4-7, and full effect by week 2-3.

There is no single sleep peptide that is universally best, and DSIP's human evidence is limited. A 1992 double-blind study found weak effects and concluded DSIP was "not likely to be of major therapeutic benefit" for chronic insomnia. DSIP is not a sedative and does not work like one.

DSIP and CJC-DAC have different mechanisms. DSIP is a neuropeptide studied for sleep architecture modulation, while CJC-1295 is a GHRH analog that stimulates growth hormone release. The two are sometimes referenced together in recovery stacks, based on the rationale that deep sleep supports GH-mediated tissue repair.

DSIP and BPC 157 target different systems. DSIP is studied for sleep regulation and neuroendocrine function, while BPC 157 is studied for tissue repair and angiogenesis. A recovery stack protocol combines them based on the rationale that healing peaks during deep sleep.

No human dosing standards exist for DSIP. The 10 mg vial strength is a research quantity. At a community-referenced dose of 100-300 mcg, the vial provides approximately 33-100 doses. This is a standard research vial size for lyophilized peptides.

DSIP 10 mg is labeled at 10 mg of DSIP per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before laboratory use.

This product page does not include a published laboratory report for the current batch. DSIP is cheap to synthesize and cheap to underdose, so a batch-specific HPLC and mass spec COA from an independent third-party lab is often recommended. For researchers requiring batch-specific testing documentation, please contact customer support.

No. DSIP has never been approved by the FDA or any regulatory authority for human use. It was removed from the FDA's Category 2 bulk-substances list in April 2026, but that removal was widely misreported as a green light. The nominations were withdrawn, there was no safety finding, and DSIP remains an unapproved new drug.